Jump to Main Content
Purification, identification and profiling of serum amyloid A proteins from sera of advanced-stage cancer patients
- Li, Jing, Xie, Zhensheng, Shi, Linan, Zhao, Zhiqiang, Hou, Junjie, Chen, Xiulan, Cui, Ziyou, Xue, Peng, Cai, Tanxi, Wu, Peng, Guo, Sutang, Yang, Fuquan
- Journal of chromatography 2012 v.889-890 pp. 3-9
- Western blotting, acetonitrile, amyloid, animal ovaries, biomarkers, blood proteins, blood serum, breast neoplasms, desorption, high performance liquid chromatography, humans, ionization, lung neoplasms, matrix-assisted laser desorption-ionization mass spectrometry, ovarian neoplasms, patients, screening
- Surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) is a powerful tool for screening potential biomarkers of various pathological conditions. However, low resolution and mass accuracy of SELDI-TOF-MS remain a major obstacle for determination of biological identities of potential protein biomarkers. We report here a refined workflow that combines ZipTip desalting, acetonitrile precipitation, high-performance liquid chromatography (HPLC) separation and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) analysis for the profiling, purification and identification of the targeted serum proteins found by SELDI-TOF-MS. By using this workflow, we purified ten targeted proteins from the sera of patients with various types of advanced stage (stage III–IV) cancers. These proteins were identified as isoforms of the human serum amyloid protein A (SAA) family with or without truncations at their N-terminals. This was confirmed by Western blot analysis. Different SAA expression patterns were observed by MALDI-TOF-MS profiling. SAA has long been reported as a biomarker for various cancer types such as lung cancer, ovarian cancer, and breast cancer. However, in this study we found increased SAA expression in the sera of advanced-stage cancer patients with different cancer types. Our results suggest that maybe SAA should not be used alone as a biomarker for any specific cancer type.